Insilico Medicine Partners to Build AI Models for Longevity Research
The collaboration with a new spinout of Human Longevity will train AI foundation models on multiomic and clinical data.
Insilico Medicine and Human Life Foundation Models (HLFM), a new spinout of Human Longevity, announced a collaboration to jointly develop AI foundation models aimed at decoding the biology of aging.
Insilico Medicine will contribute model architecture, benchmarking, training guidelines, and computational algorithms. HLFM will integrate those tools with Human Longevity’s de-identified multiomic and clinical datasets.
The companies said the jointly developed models are intended to support early detection of age-related diseases, predictive health risk modeling, and the discovery of therapeutics and personalized interventions.
In a statement, the partners described the deal as a “multi-million-dollar collaboration,” however, they did not provide more detail and no timeline for commercial availability of the models was disclosed.
“Human longevity and healthspan represent one of the most complex challenges in biology, “ Alex Zhavoronkov, CEO and founder of Insilico Medicine said in a statement. “By combining Insilico’s expertise in generative AI drug discovery and multimodal foundation models with HLFM’s unique datasets [...] we aim to build a next-generation AI system capable of decoding the biology of aging.”
Insilico Medicine said it has published more than 50 research papers on aging, longevity biomarkers, and related therapeutics since 2014. Insilico also said it recently formed a longevity advisory board chaired by Andrew Adams, group VP of molecular discovery at Eli Lilly.
Earlier this year, Insilico Medicine and Eli Lilly signed a development agreement with a $115 million up-front payment and could be worth up to $2.75 billion.